201 related articles for article (PubMed ID: 21396130)
1. A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.
Tsang TW; Kohn MR; Hermens DF; Clarke SD; Clark CR; Efron D; Cranswick N; Lamb C; Williams LM
Trials; 2011 Mar; 12():77. PubMed ID: 21396130
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
[TBL] [Abstract][Full Text] [Related]
3. Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.
Griffiths KR; Leikauf JE; Tsang TW; Clarke S; Hermens DF; Efron D; Williams LM; Kohn MR
J Psychiatr Res; 2018 Jul; 102():57-64. PubMed ID: 29674270
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
Geller D; Donnelly C; Lopez F; Rubin R; Newcorn J; Sutton V; Bakken R; Paczkowski M; Kelsey D; Sumner C
J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1119-1127. PubMed ID: 17712235
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
7. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Biederman J; Spencer TJ; Newcorn JH; Gao H; Milton DR; Feldman PD; Witte MM
Psychopharmacology (Berl); 2007 Jan; 190(1):31-41. PubMed ID: 17093981
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder.
Khoodoruth MAS; Ouanes S; Khan YS
Res Dev Disabil; 2022 Sep; 128():104275. PubMed ID: 35691145
[TBL] [Abstract][Full Text] [Related]
9. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
10. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
Martenyi F; Zavadenko NN; Jarkova NB; Yarosh AA; Soldatenkova VO; Bardenstein LM; Kozlova IA; Neznanov NG; Maslova OI; Petrukhin AS; Sukchotina NK; Zykov VP
Eur Child Adolesc Psychiatry; 2010 Jan; 19(1):57-66. PubMed ID: 19568826
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng JY; Chen RY; Ko JS; Ng EM
Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.
Spencer TJ; Faraone SV; Michelson D; Adler LA; Reimherr FW; Glatt SJ; Biederman J
J Clin Psychiatry; 2006 Mar; 67(3):415-20. PubMed ID: 16649828
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.
Svanborg P; Thernlund G; Gustafsson PA; Hägglöf B; Poole L; Kadesjö B
Eur Child Adolesc Psychiatry; 2009 Apr; 18(4):240-9. PubMed ID: 19156355
[TBL] [Abstract][Full Text] [Related]
19. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
Hazell P; Zhang S; Wolańczyk T; Barton J; Johnson M; Zuddas A; Danckaerts M; Ladikos A; Benn D; Yoran-Hegesh R; Zeiner P; Michelson D
Eur Child Adolesc Psychiatry; 2006 Mar; 15(2):105-10. PubMed ID: 16523251
[TBL] [Abstract][Full Text] [Related]
20. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
Leuchter AF; McGough JJ; Korb AS; Hunter AM; Glaser PE; Deldar A; Durell TM; Cook IA
J Psychiatr Res; 2014 Jul; 54():11-8. PubMed ID: 24726639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
